Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab + bendamustine vs bendamustine in rituximab-unresponsive indolent B-cell non-Hodgkin's lymphoma (Japan)
jRCT2080221922Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in low-grade B-cell lymphoma comparing Ofatumumab + bendamustine with Bendamustine monotherapy (2 arms). Started Sep 2012; status: completed.
02
Drugs
ofatumumabbendamustine
03
Conditions
low-grade B-cell lymphoma
Beyond the preview
Go deeper on jRCT2080221922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221922.